A phase II clinical trial of anti-Tac(Fv)-PE38 (LMB-2) immunotoxin for treatment of CD25 positive cutaneous T-cell lymphomas.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Anti-Tac Fv PE38 conjugate (Primary)
- Indications Cutaneous T-cell lymphoma
- Focus Therapeutic Use
- 29 Jan 2018 Biomarkers information updated
- 04 Jan 2012 Actual patient number is 9 according to ClinicalTrials.gov.
- 04 Jan 2012 Actual patient number is 9 according to ClinicalTrials.gov.